Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study

Carfilzomib-mediated cardiotoxicity in multiple myeloma (MM) is a well-established adverse effect, however limited data are available on the comparison of cardiovascular complications in patients treated with Carfilzomib-dexamethasone (target dose of K 56 mg/m<sup>2</sup>) versus Carfilz...

Full description

Bibliographic Details
Main Authors: Anna Astarita, Giulia Mingrone, Lorenzo Airale, Marco Cesareo, Anna Colomba, Cinzia Catarinella, Dario Leone, Francesca Gay, Sara Bringhen, Franco Veglio, Alberto Milan, Fabrizio Vallelonga
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
carfilzomib
cardiotoxicity
Kd
KRd
real-life
dexamethasone
Online Access:https://www.mdpi.com/2072-6694/15/3/955

Similar Items

Similar Items